Swipe Left For English News
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，公司凭借在可持续发展领域的卓越表现，入选标普全球（S&P Global）《可持续发展年鉴2024》（以下简称《年鉴》）。
该《年鉴》基于标普全球企业可持续发展评估 (CSA)，评选出各行业在可持续发展方面表现优异的企业。在2023年CSA评估的9400多家企业中，759家企业脱颖而出，成功入选该《年鉴》。药明生物在本次CSA评估中排名前1%。
2023 年，药明生物的温室气体排放密度相比2020年基线下降29%。公司还提前完成用水密度降低的节水目标，并将这一目标从到2025年相较于2019年基线降低18%提升至30%。药明生物积极倡导多元化、平等和包容（DEI）的理念，女性管理者占比达47%，从事科学、技术、工程和数学（STEM）岗位的女性员工比例高达53%。
陈智胜博士
首席执行官
ESG委员会主席
药明生物
我们很高兴成功入选标普全球《可持续发展年鉴2024》，这是继入选2023年标普道琼斯可持续发展世界指数（DJSI World）和道琼斯新兴市场指数（DJSI Emerging Markets Index）后的又一佳绩。这些成就充分肯定了我们不断致力于提升环境、社会和公司治理能力，持续推动公司ESG卓越发展，以及为全球合作伙伴及社会公众创造更大价值的坚定承诺。
药明生物始终将可持续发展视为企业发展战略的基石。在过去的一年中，公司在ESG领域取得了具有里程碑意义的成就：6月，公司宣布签署科学碳目标倡议（SBTi）承诺书，旨在支持到2050年实现温室气体净零排放的目标；9月，公司加入联合国全球契约组织（UNGC），以履行其在可持续发展议题上的承诺；11月，公司获得明晟公司（MSCI）ESG评级中的AAA评级和国际权威企业可持续发展评估机构EcoVadis “铂金”评级，均为对获评企业的最高认可。
推荐阅读
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物人的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2023年12月底，药明生物帮助客户研发和生产的综合项目高达698个，其中包括24个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Selected for S&P Global Sustainability Yearbook 2024
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been selected for the S&P Global Sustainability Yearbook 2024 ("Yearbook") for its strong sustainability performance in 2023.
The Yearbook aims to distinguish individual companies within a range of industries that have demonstrated strong corporate sustainability, based on the S&P's Corporate Sustainability Assessment (CSA). Over 9,400 companies were assessed in the 2023 CSA, and 759 top-performing companies were selected for the 2024 Yearbook. WuXi Biologics received a Top 1% S&P Global CSA Score.
In 2023, WuXi Biologics realized a 29% greenhouse gas emission intensity reduction from the base year 2020. In addition, the company achieved water consumption intensity reduction target ahead of schedule, and upgraded the target from 18% to 30% intensity reduction by 2025 from the base year 2019. Actively promoting Diversity, Equity and Inclusion (DEI), WuXi Biologics has 47% female employees in managerial positions and 53% STEM positions are held by female employees.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very pleased to be named in the S&P Global Sustainability Yearbook 2024, which follows our inclusion into the Dow Jones Sustainability World Index and the Dow Jones Sustainability Emerging Markets Index last year. These achievements are a reflection of our deep commitment to continually enhancing our ESG capabilities and further driving the company's sustainable growth for the common good of the global community.
WuXi Biologics regards sustainability as the cornerstone of its business. In the past year, it has achieved a number of notable ESG milestones. In June, the company signed the Science Based Targets initiative (SBTi) commitment letter, a new pledge in support of the goal to achieve net-zero greenhouse gas emissions by 2050. In September, the company also became a participant to the United Nations Global Compact, further demonstrating its sustainability commitment. In November, WuXi Biologics received an AAA rating from MSCI ESG Ratings and an EcoVadis Sustainability Rating's Platinum Medal, the highest recognition granted to the companies being evaluated.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
